Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe

Paying for Prescription Drugs in the New Administration

(2021) Aaron S. Kesselheim et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis

(2020) Kerstin N Vokinger et al.   LANCET ONCOLOGY

Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany

(2020) Victoria D. Lauenroth et al.   HEALTH AFFAIRS

Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study

(2020) Thomas J Hwang et al.   BMJ-British Medical Journal

Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score

(2019) Nathan I. Cherny et al.   JOURNAL OF CLINICAL ONCOLOGY

Price Increases of Protected-Class Drugs in Medicare Part D, Relative to Inflation, 2012-2017

(2019) Thomas J. Hwang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis

(2019) Huseyin Naci et al.   BMJ-British Medical Journal

Financial Toxicity in Adults With Cancer: Adverse Outcomes and Noncompliance

(2018) Thomas G. Knight et al.   Journal of Oncology Practice

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received

(2016) Lowell E. Schnipper et al.   JOURNAL OF CLINICAL ONCOLOGY

Public referendum on drug prices in the US: will it bring relief?

(2016) Thomas J Hwang et al.   BMJ-British Medical Journal

Public referendum on drug prices in the US: will it bring relief?

(2016) Thomas J Hwang et al.   BMJ-British Medical Journal

How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers’ views

(2013) G. Tafuri et al.   ANNALS OF ONCOLOGY

Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

(2013) Stacie B. Dusetzina et al.   JOURNAL OF CLINICAL ONCOLOGY